BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today reported financial results for the third quarter of 2022 and recent business highlights. “We are fulfilling our commitment to make a difference in the lives of individuals with rare muscle disorders,” said Kevin Koch, Ph.D., President and Chief Executive Offic
Click here to view original post
News
Five Mobility Exercises for Low Back Pain
One of the most common things Amy Wallace McDevitt, DPT, PhD, sees in her patients with low back pain is fear. Click here to view original post Click Here to Publish/Feature Your Company or Product […]
News
Edgewise Therapeutics to Present at the Wedbush PacGrow Healthcare Conference on August 9
BOULDER, Colo.–(BUSINESS WIRE)–Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today that members of its senior management team […]
News
InterviewIA’s health care brand acquires notable Boulder startup
Denver and Boulder startups are joining forces to make hiring more equitable. Click here to view original post Click Here to Publish/Feature Your Company or Product News with Biotech Networks
